



GlaxoSmithKline
PO Box 13398
5 Moore Drive
Research Triangle Park
North Carolina 27709
Tel. 919 483 2100
www.gsk.com

Attention Healthcare Professional:

FLOVENT® ROTADISK® (fluticasone propionate inhalation powder) has been approved in the United States for 7 years as an effective treatment for asthma. FLOVENT ROTADISK is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirement for oral corticosteroids over time.

GlaxoSmithKline has decided to phase out FLOVENT ROTADISK based on a careful assessment of the product's current manufacturing process needs, current low product volumes utilized, and the availability of alternative therapies for the treatment of asthma. GlaxoSmithKline will begin to exhaust supplies of the 3 strengths as early as September 2004. **Please note that this phaseout applies only to the ROTADISK formulation.** Other fluticasone propionate-containing products, such as FLOVENT® (fluticasone propionate) Inhalation Aerosol 44 mcg, 110 mcg, and 220 mcg, will continue to be supplied to the US market.

FLOVENT Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirement for oral corticosteroids over time.

Be assured that GlaxoSmithKline, a pioneer in medical research, remains committed to the development of respiratory medications and the treatment of patients with asthma.

For questions pertaining to the phaseout of FLOVENT ROTADISK, please call GlaxoSmithKline at 1-888-825-5249.

Sincerely,

Kathleen A. Rickard, MD
Vice President
Respiratory Medicine Development Center, North America

Important Information:

FLOVENT is NOT indicated for the relief of acute bronchospasm.

Adrenal insufficiency may occur when transferring patients from systemic steroids to inhaled corticosteroids (see WARNINGS in complete Prescribing Information).

Please see accompanying complete Prescribing Information.